Last reviewed · How we verify
Chronic idiopathic urticaria
Approved treatments
- Xyzal · Sanofi
- Allegra · Generic (originally Hoechst Marion Roussel/Sanofi)
- Seldane
- Hismanal
- Xolair · Roche
- Zyrtec · Generic (originally UCB Pharma)
- Xolair · Taizhou Mabtech Pharmaceutical Co.,Ltd
- Clarinex · Generic (originally Schering-Plough/MSD)
Active metabolite of loratadine with higher potency at H1 receptors and additional anti-inflammatory properties. - Claritin · Generic (originally Schering-Plough)
- Bastel
- Desloratadin · Max Zeller Soehne AG
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Chronic idiopathic urticaria patent landscape — cliff calendar, originator estates, attackable patents
- Chronic idiopathic urticaria treatment landscape brief
- Chronic idiopathic urticaria treatment updates RSS
Frequently asked questions about Chronic idiopathic urticaria
What drugs treat Chronic idiopathic urticaria?
Tracked treatments include Xyzal, Allegra, Seldane, Hismanal, Xolair, Zyrtec, Clarinex, Claritin.
What is the treatment for Chronic idiopathic urticaria?
Standard treatment for Chronic idiopathic urticaria includes Xyzal, Allegra, Seldane, Hismanal, Xolair. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Chronic idiopathic urticaria patent cliff · Chronic idiopathic urticaria CI report
- Treatment: Xyzal · Sanofi
- Treatment: Allegra · Generic (originally Hoechst Marion Roussel/Sanofi)
- Treatment: Seldane
- Treatment: Hismanal
- Treatment: Xolair · Roche
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing